A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

NCT07103668 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma

Interventions

DRUG: CAR T cells
DRUG: Control

Sponsor

Suzhou Immunofoco Biotechnology Co., Ltd